NCT00198588已完成3 期
Open-Label Trial to Evaluate the Efficacy and Safety of the Use of Argatroban in Patients With Heparin-Induced Thrombocytopenia
Ministry of Health, Labour and Welfare, Japan40 个研究点 分布在 1 个国家目标入组 8 人开始时间: 2005年6月1日最近更新:
适应症
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 入组人数
- 8
- 试验地点
- 40
- 主要终点
- Death, new thrombosis, amputation
研究概览
简要总结
The purpose of the study is to evaluate efficacy and safety of argatroban in the patients with heparin-induced thrombocytopenia (HIT)/ HIT and thrombosis syndrome (HITTS). This multi-center trial covers mainly the patients with cardiovascular diseases. Subjects are included in the trial when they are clinically diagnosed of HIT/HITTS. Initial dose of argatroban is 0.7μg/kg/min, which is about one-third of the approved dose in the US. The reason of the lower initial dose is that the approved dose of argatroban in Japan (for the treatment of ischemic stroke) is about 0.7μg/kg/min and safety of higher doses of the drug are not confirmed. A sub-study of pharmacokinetics is simultaneously conducted to reveal the relationship among the dose, aPTT, and blood drug concentration.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 20 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Males of non-pregnant females >=20 and <=80 years of age
- •Those with the diagnosis of HIT or HITTS made by the following diagnostic criteria, or those who have positive results of HIT antibody
- •diagnostic criteria of HIT
- •a fall in platelet count to less than 100,000/μL or a 50% decrease in platelets after the initiation of heparin therapy with no apparent explanation other than HIT
- •diagnostic criteria of HITTS
- •those who met the diagnosis criteria of HIT
- •presence of an arterial or venous thrombosis documented by appropriate imaging technique (ultrasound, angiography etc.) or supported by clinical evidence such as a myocardial infarction, stroke, pulmonary embolism, or other clinical indications of vascular occlusion(absence of pulse, cold, cyanotic extremities, etc.)
- •patients with history of HIT/HITTS with positive test results (HIT antibody or platelet function test) could be enrolled without present thrombocytopenia
- •patients willing and able to give informed consent
排除标准
- •any condition which in the investigator's opinion, contraindicated the use of argatroban or endangered the patient if he or she participated in this trial
- •clinically significant or uncontrolled endocrine, renal, pulmonary, gastrointestinal, or psychiatric disorder of sufficient severity that the investigator deemed antithrombotic therapy with argatroban to be contraindicated
- •unexplained aPTT>200% of control at baseline
- •documented coagulation disorder or unexplained bleeding diathesis unrelated to HIT
- •lumbar puncture within the past 7 days
- •known clinical site of bleeding. Patients with a known site of clinical bleeding could be enrolled if the investigator deemed the risk of continued thrombosis outweighed the potential bleeding risk
- •serious liver disfunction
- •females of known or suspected pregnancy
- •breast feeding females
- •participation in other clinical drug trials within the past 30 days
- •history of hypersensitivity to argatroban
- •concomitant use of cimetidine
- •previous participation in this trial
结局指标
主要结局
Death, new thrombosis, amputation
时间窗: till 37 days
次要结局
- Achievement of anticoagulation therapy(till 37 days)
- Improvement of thrombocytopenia(till 37 days)
研究者
研究点 (40)
Loading locations...
相似试验
进行中（未招募）
4 期
Clinical Study to Assess the Efficacy and Safety of Olaparib in Chinese Patients With Metastatic Castration-Resistant Prostate Cancer Who Have Failed Prior Treatment With a New Hormonal Agent and Have BRCA1/2 MutationsMetastatic Castration-resistant Prostate CancerNCT05457257AstraZeneca43
已完成
2 期
Clinical Management of Argatroban in Patients With Heparin Induced Thrombocytopenia Type IIHeparin-induced Thrombocytopenia Type IINCT00861692Tanabe Pharma Corporation20
已完成
3 期
Open Label Study to Evaluate Effect, Safety and Tolerability of Betaferon Standard Dose of 250µg in Patients of Chinese Origin With Multiple SclerosisMultiple SclerosisNCT00370071Bayer39
已完成
4 期
A Study of MabThera (Rituximab) in Patients With Rheumatoid Arthritis and an Inadequate Response to MethotrexateRheumatoid ArthritisNCT01000610Hoffmann-La Roche18
撤回
3 期
Open-Label Study to Evaluate the Safety and Efficacy of Avatrombopag and Remission Rates in Adults With ITP of ≤6 MonthsImmune ThrombocytopeniaNCT05046327Sobi, Inc.